Glycerol
Glycerol (glycerin) is an osmotic agent used as a rectal suppository or enema for the short-term relief of constipation, and also has applications as an emollient and pharmaceutical excipient.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
When administered rectally it acts as a hyperosmotic and mild local irritant, drawing water into the bowel and stimulating rectal evacuation.
Prescribing in practice
- It is intended for short-term relief of occasional constipation; persistent or recurrent symptoms warrant assessment for an underlying cause rather than continued laxative use.
- Rectal preparations may cause local irritation or a burning sensation on administration.
- Moistening the suppository before insertion can aid administration and patient comfort.
Monitoring
Routine laboratory monitoring is not required; review the response and reassess if constipation persists despite treatment.
Counselling the patient
- This is for short-term relief; see your clinician if constipation continues or recurs.
- Maintaining adequate fluid intake, fibre and activity helps prevent constipation.
Evidence & guidelines
Osmotic and stimulant laxatives are established options for the management of constipation in line with NICE guidance.
Reference: NICE CKS constipation; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021